TAT-based Y211F cell-penetrating PCNA peptide (CPPP) has been reported to be effective in suppressing the proliferation of TNBC (triple negative breast cancer) cells that have become treatment resistant, especially to EGFR TKI [77]. The gene discussed is PCNA; the disease is triple-negative breast carcinoma.